Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Gains from Investment Securities (2023 - 2026)

ArriVent BioPharma has reported Gains from Investment Securities over the past 4 years, most recently at $7.2 million for Q1 2026.

  • Quarterly results put Gains from Investment Securities at $7.2 million for Q1 2026, up 77.88% from a year ago — trailing twelve months through Mar 2026 was $7.2 million (up 77.88% YoY), and the annual figure for FY2025 was $4.3 million, up 71.02%.
  • Gains from Investment Securities reached $7.2 million in Q1 2026 per AVBP's latest filing, up from $4.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $7.2 million in Q1 2026 and bottomed at $801091.0 in Q4 2023.
  • Median Gains from Investment Securities over the past 4 years was $2.3 million (2024), compared with a mean of $2.9 million.
  • The largest annual shift saw Gains from Investment Securities soared 215.96% in 2024 before it grew 3.05% in 2025.
  • Over 4 years, Gains from Investment Securities stood at $801091.0 in 2023, then skyrocketed by 215.96% to $2.5 million in 2024, then surged by 71.02% to $4.3 million in 2025, then soared by 66.8% to $7.2 million in 2026.
  • Business Quant data shows Gains from Investment Securities for AVBP at $7.2 million in Q1 2026, $4.3 million in Q4 2025, and $2.0 million in Q3 2025.